Extended report: Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis juvenile idiopathic arthritis ankylosing spondylitis psoriatic arthritis psoriasis and Crohns disease

摘要

BackgroundAs long-term treatment with antitumour necrosis factor (TNF) drugs becomes accepted practice, the risk assessment requires an understanding of anti-TNF long-term safety. Registry safety data in rheumatoid arthritis (RA) are available, but these patients may not be monitored as closely as patients in a clinical trial. Cross-indication safety reviews of available anti-TNF agents are limited.